Author: Vivian Xie 4th June 2026

In a pharmaceutical landscape transformed by geopolitical upheaval, technological disruption, and regulatory evolution, industry leaders need transformative intelligence that can guide decision making in this era of profound change. CPHI Americas arrives at precisely the right moment to shape the industry’s future, with a curated program of sessions that directly address the most pressing challenges facing pharmaceutical manufacturing, biotech innovation, and regulatory compliance. This year's conference agenda reflects the industry's urgent need to recalibrate its strategies and reimagine manufacturing for a new era.

The sessions highlighted in this article represent the essential conversations that bring regulatory insiders, innovation thought leaders and strategic visionaries together to define the industry's trajectory for years to come. From understanding how the FDA's evolving response to supply chain security concerns to grappling with the cognitive implications of AI-driven decision-making in GMP environments, these sessions offer the kind of actionable intelligence that transcends typical conference programming.

Whether you're a C-suite executive charting long-term strategy, a manufacturing leader optimizing operations, or an innovation strategist positioning your organization for future growth, these sessions deliver the insights, frameworks, and foresight to help you move through an uncertain present with confidence. If you're serious about future-proofing your organization, these are the conversations you cannot afford to miss.

From Globalization to Geoeconomics: U.S. Pharmaceutical Manufacturing in a New Reality

For decades, U.S. pharmaceutical manufacturing operated within a globally optimized system built on scale, cost efficiency, and technical capability, not to mention ensuring regulatory alignment across any major international markets. That system is now under sustained pressure as trade policy shifts, reshoring incentives, and supply chain vulnerability prompt leaders to reassess where and how to make manufacturing investments serving the U.S. market.

Site decisions are never purely a question of cost; they reflect broader economic ecosystems that determine access to talent, infrastructure, and long-term competitiveness. This keynote examines how global forces are reshaping manufacturing strategy for companies operating in or supplying the United States, distinguishing short-term political cycles from more durable structural change. It will provide context for the following panel discussion, linking these forces to the investment, technology, procurement, and market decisions defining the future of American pharma.

Inside the FDA: What's Happening Now and What's Coming Next?

Dr. Richard Pazdur stood at the center of drug regulation at the FDA, with more than two decades under his belt as Director of the Center for Drug Evaluation and Research and the Oncology Center of Excellence. Now, in an exclusive and candid conversation, he steps outside the agency to share an insider’s view rarely heard outside of its Maryland HQ.

The FDA's expectations around supply chain security have shifted dramatically in response to tariff pressures, reshoring mandates, and heightened national security concerns. Drawing directly from his 26 years shaping FDA policy, Dr. Pazdur reveals how regulators are assessing vulnerabilities, what compliance standards are being enforced today, and how these changes are reshaping approval pathways and market access for every company supplying the U.S. market.

This session delivers the rare, unfiltered regulatory intelligence needed to move beyond guesswork, showing how FDA thinking is evolving and what it means for risk mitigation, diversification strategies, and long-term competitiveness in the sector. If you want to understand the regulatory landscape, its impact on your supply chain, and how to turn these challenges into opportunities, this is the session you can't afford to miss.

The Evolving Biotech Innovation Ecosystem: What's Ahead?

The biotech innovation ecosystem is at a critical turning point, and this keynote will explore the forces driving its transformation. From novel modalities to the strategic collaborations shaping the future, dive into the trends redefining what's possible in biotechnology, the shifting investment landscape, and how the global mix of clinical trial activity is shifting. Join us for an inspiring session that will challenge your thinking and spark new ideas about the opportunities and challenges ahead in this dynamic field.

Operational Excellence in the Age of AI

Artificial intelligence is  reshaping how we think and make decisions, and in the pharma industry, we're moving into a world where answers arrive fully formed in the form of AI-driven quality decisions, predictive maintenance alerts, and automated batch release recommendations. The friction that once deepened understanding is disappearing to powerful systems which operate without experience or consequence, creating a new tension: fluency without judgment.

Drawing on two decades of work at the intersection of technology, medicine, and human cognition, including advisory roles with Roche, the World Health Organization, and Google Health, alongside a scientific foundation in cardiovascular physiology, John Nosta explores this shift as less of a warning than a design challenge. With the key question of how we engage these tools and preserve the human side of pharma, this talk examines what happens to decision-making when AI removes the hard work of analysis, why that matters in regulated environments where judgment is non-negotiable, and how we can use these systems in ways that keep human thinking central to operational excellence.

Future-Proofing Pharma: Navigating Uncertainty Through Science-Driven Sustainability and Policy Leadership

The policy storm is here, in a torrent of geopolitical volatility, pricing reforms, IRA fallout, tariff threats, and accelerating regulatory divergence. This high-level keynote cuts through the noise to reveal actionable strategies for thriving amid uncertainty. From scenario planning and policy advocacy to resilient supply-chain design and next-era market access models, discover how leading firms are turning risk into proprietary advantage. Don’t miss this essential intelligence for any executive shaping 2030+ strategy in an era where policy moves faster than science.

With this program, CPHI Americas has set out to reflect the industry's most pressing needs and most promising opportunities. These five sessions stand out as the conversations that will shape strategic thinking, inform investment decisions, and influence how leading organizations navigate the decade ahead. Make them a priority in your schedule; the insights you gain will prove invaluable as your business addresses the challenges and opportunities that define this transformative moment in pharmaceutical history.